Regardless of what, in just 2 months, the BMS/IMCL commercial agreement leaves both parties to develop & market in N. America any product including ones directly competing with C225 (Erbitux).
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.